Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Uridine deficiency, in the context of replacement therapy, refers to a systemic lack of uridine nucleotides due to impaired de novo pyrimidine biosynthesis, most commonly seen in hereditary orotic aciduria. Uridine replacement, typically using uridine triacetate, aims to restore intracellular pyrimidine pools, bypassing the defective UMPS enzyme and enabling normal nucleotide synthesis. This approach is used to manage the symptoms and complications of UMPS deficiency.
Restores intracellular pyrimidine nucleotide pools by bypassing the defective de novo synthesis pathway through salvage pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uridine Deficiency (Replacement) (N/A).